| Literature DB >> 35300756 |
Mikkel Roulund Wilken1, Max Norman Tandrup Lambert1, Christine Bodelund Christensen1, Per Bendix Jeppesen1.
Abstract
OBJECTIVE: Metabolic syndrome (MetS) can lead to fatal complications, including cardiovascular disease. Emerging evidence suggests has emerged that increased fruit and vegetable intake and decreased intake of saturated fats, simple sugars, and processed foods can improve cardiovascular health. Anthocyanins (color pigments) have anti-inflammatory and antioxidant capacities but are of low bioavailability. In this systematic review and metaanalysis, we investigate the possible beneficial effects of the intake of berries high in anthocyanins on MetS risk factors. We also investigate the influences of high-density lipoprotein (HDL), lowdensity lipoprotein (LDL), triglycerides (TG), and total cholesterol (TC).Entities:
Mesh:
Substances:
Year: 2022 PMID: 35300756 PMCID: PMC9382680 DOI: 10.1900/RDS.2022.18.42
Source DB: PubMed Journal: Rev Diabet Stud ISSN: 1613-6071
Figure 1.The figure illustrates the process of OX-LDL binding to LOX-1 receptor with subsequently increased transcription of LOX-1 mRNA as well as adhesion protein mRNA.
Summary of possible mechanisms underlying blood lipid improvements seen in preclinical and clinical studies
| Authors | Treatment/ dose | Type of study | Number of participants | Potential mechanism | Health benefits |
|---|---|---|---|---|---|
| Yanna Zhu et al. (2014) [ | 320 mg/d anthocyanins from bilberries and black currants | Human study, double-blinded, RCT | 122 hypercholesterolemic patients | Activation of PON1 HDL oxidization and breakdown ReCT | Increase in serum HDL and possible decrease in serum LDL |
| Nicholas Farrell et al. (2015) [ | Anthocyanin-rich diet | Mouse study | 36 male Apo-/-mice (24 on anthocyanin diet, 12 on control diet) | ApoA1 transcription PON1 transcription Serum amyloid A1, lectin cholesterol acyltransferase transcription Apolipoprotein J transcription Chemokines and serum CCL2 | Improved HDL function and lowered inflammation |
| Qin, Y. et al. (2009) [ | 320 mg/d anthocyanins | Human study, double blinded, RCT | 20 dyslipidemic subjects | CETP activity | Decreased formation of LDL, VLDL, and IDL |
| Erl-Shyh Kao et al. (2009) [ | 0.05-0.2 mg/ml anthocyanins from Hibiscus | J774A.1-cells treated with OX-LDL to induce foam cell formation | CD36 Foam cell formation | Reduction in foam cell formation | |
| Kim et al. (2018) [ | 50 or 100 gg/ml anthocyanins from black currants | Caco-2 cells | Low-density lipoprotein receptor | Increased cellular uptake of LDL resulting in decreased serum LDL levels | |
| Pei-Wen Zhang et al. (2015) [ | 320 mg/d blueberry and black currant anthocyanin extract | Human study, double blinded, RCT | 74 (39 men and 35 women) | ApoA-B ApoA-C | Reduction in CVD and CHD risk[ |
| HonghuiHuo et al. (2012) [ | Cyanidin-3- glucoside treatment | 3T3-L1 adipocytes | ATGL activity | Decreased serum TG levels |
Legend: ApoA1 - apolipoprotein A1, ATGL - adipose triglyceride lipase, CETP - cholesteryl ester transfer protein, CCL2 - chemokines and ligand 2, CVD - cardiovascular disease, HDL - high-density lipoprotein, IDL -intermediate-density lipoproteins, LDL - low-density lipoproteins, PON1 -paraoxonase and arylesterase 1, ReCT- reverse cholesterol transport, RCT - randomized controlled trial.
Figure 2.Study flow diagram showing the different steps in screening of articles obtained from PUBMED and EMBASE and the reasons for exclusions
Figure 3.Risk of bias summary of authors. Green = low risk of bias, red = high risk of bias.
Summary of studies included in the meta-analysis
| Study | Study type | Participant characteristics | Number of participants (age) | Duration | Intervention | Placebo | Country |
|---|---|---|---|---|---|---|---|
| Aghababaee (2015) <span style=”baseline”> 59]</span> | RCT | Dyslipidemia | Inv: 36 (45.08±7.58) Con: 36 (45.61±8.69) | 8 weeks | 300 ml/d blackberry juice with pulp | Usual diets | Iran |
| Arvestöm (2018) <span style=”baseline”>[ | RCT | Dyslipidemia | Inv: 25 (66 (62-71)) Con: 25 (68 (62-74)) | 8 weeks | 10 g freeze-dried bilberries in capsules | Capsules with bilberry flavor | Sweden |
| Amani (2014) <span style=”baseline”>[ | RCT | T2DM | Inv: 19 (51.9±8.2) Con: 17 (51.1±13.8) | 6 weeks | Freeze-dried strawberry beverages (25g/d powder) | Isocaloric drink with strawberry flavor | Iran |
| Burton-Freeman (2010)<span style=”baseline”>[ | RC | Dyslipidemia | Inv: 12 Con: 12 (50.9±15.0) | 2x6 weeks | Strawberry drink containing 10 g/d freeze- dried strawberry | Drink matched in energy and macronutrients | USA |
| Basu (2010) <span style=”baseline”>[ | RCT | MetS | Inv: 15 (45.0±3.0) Con: 12 (48.0±5.3) | 8 weeks | Strawberry drink containing 50 g/d freeze- dried strawberry | 4 cups of water | USA |
| Basu (2011) <span style=”baseline”>[ | RCT | MetS | Inv: 15 Con: 16 (52.0±8.0) | 8 weeks | 480 ml/d cranberry juice | 480 ml/d placebo drink | USA |
| Basu (2014) <span style=”baseline”>[ | RCT | Dyslipidemia | LD-FDS: 15 (50±10) LD-C: 15 (48±10) HD-FDS: 15(49±11) HD-C: 15 (48±10) | 12 weeks | LD-FDS: 25 g/d HD-FDS: 50 g/d Freeze-dried strawberry powder | Red food color, strawberry- flavored, fibers from vegetables and gums | USA |
| Curtis (2019) <span style=”baseline”>[ | RCT | MetS | Inv 1: 39 (62.6±7.2) Inv 2: 37 (63.0±5.9 Con: 39 (62.9±8.1) | 6 months | Inv 1: % cup blueberries Inv 2: 1 cup blueberries | Isocaloric and macronutrientmatching food | UK |
| Kanellos (2014) <span style=”baseline”>[ | RCT | T2DM | Inv: 26 (63.7±6.3) Con: 22 (63±8.5) | 24 weeks | 36g/d of Corinthian raisins,fewer fruits and vegetables than usual | Usual diet,fewer grapes and raisins | Greece |
| Kianbakht (2014) <span style=”baseline”>[ | RCT | Dyslipidemia | Inv: 40 (51.3±15.27) Con: 40 (55.8±13.28) | 2 months | 4 times daily consumption of capsules containing 2.45 mg anthocyanin each | 4 times daily consumption of placebo capsule containing no anthocyanin | Iran |
| Li (2015)<span style=”baseline”>[ | RCT | T2DM | Inv: 29 (57.6±3.4) Con: 29 (58.1±2.3) | 24 weeks | 160 mg anthocyanin capsule twice daily | Placebo capsule containing no anthocyanin twice daily | China |
| Mirfeizi (2016)<span style=”baseline”>[ | RCT | T2DM | Inv: 30 (55±10) Con: 45 (54±12) | 90 days | 1 g/d of whortleberry | Starch capsules | Iran |
| Mulero (2012)<span style=”baseline”>[ | RCT | Dyslipidemia | Inv: 18 Con: 15 | 6 months | 300 ml citrus juice including aronia berry extract once daily | 300 ml citrus juice once daily | Spain |
| Novotny (2015)<span style=”baseline”>[ | RCT | Dyslipidemia | Inv: 29 (49.8±11.3) Con: 27 (51.3±11.1) | 8 weeks | 240 ml/d low-calorie cranberry juice | Placebo product, unclear masking | USA |
| Paquette (2017) <span style=”baseline”>[ | RCT | Dyslipidemia | Inv: 20 (57±1) Con: 21 (60±1) | 6 weeks | Beverage containing 333 mg strawberry and cranberry polyphenols | Flavor- matched drink containing no polyphenols | Canada |
| Ruel (2008) <span style=”baseline”>[ | RC | Dyslipidemia | Inv 1: 30 Inv 2: 30 Inv 3: 30 Con: 30 (51±10) | 4x4 weeks | Inv 1: 125 mlcranberry juice + 375ml placebo drink Inv 2: 250 mlcranberry juice + 250 ml placebo drink Inv 3: 500 mlcranberry juice | Control: 500 ml placebo drink | Canada |
| Xie (2017) <span style=”baseline”>[ | RCT | Dyslipidemia | Inv: 25 (32.6±2.6) Con: 24 (37.4±3.0) | 12 weeks | 2 capsules daily providing 500 mg/d of aronia extract | 2 placebo capsules identical in color and appearance daily | USA |
| Javid (2018) <span style=”baseline”>[ | RCT | T2DM | Inv: 9 (57.88±6.03) Con: 12 (53.60±6.23) | 8 weeks | 200 ml/d cranberry juice | No placebo product | Iran |
| Zhang (2015) <span style=”baseline”>[ | RCT | NAFLD | Inv: 37 (44.9±7.5) Con: 37(46.9±7.7) | 12 weeks | 320 mg anthocyanin- containing capsules from bilberry and black currant | Placebo capsules | China |
| Zhu (2011) <span style=”baseline”>[ | RCT | Dyslipidemia | Inv: 73 Con: 73 | 12 weeks | 320 mg anthocyanin/day | Placebo capsule containing no anthocyanin | China |
| Zunino (2011) <span style=”baseline”>[ | RC | Dyslipidemia | Inv: 20 Con: 20 Male: 29.4+6.6 Female: 31.8±11.4 | 7 weeks | Diets provided 7/d/week containing 4 servings strawberries/day | Diets provided 7/d/week containing no strawberry powder | USA |
Legend: Age given with ±SD, SEM, or range if provided. If age was not provided in articles per group for intervention and control groups, age shown is for both groups and sexes combined. Abbreviations: Inv -intervention group, Con -control group, LD-FD -low-dose freeze-dried strawberries, HD-FDS -high-dose freeze-dried strawberries, LD-C -low-dose freeze-dried strawberry control group, HD-C -high-dose freeze-dried strawberry control group, RC - randomized crossover, RCT - randomized controlled trial, T2DM - type 2 diabetes mellitus.
Figure 4.Forest plot showing the effects of the intervention included in the meta-analysis on HDL levels. Data are presented as mean difference and 95% CI using a random-effect model.
Figure 5.Forest plot showing the effects of cranberry intervention on HDL levels. Data are presented as mean difference and 95% CI using a random-effect model.
Figure 6.Forest plot showing the effects of intervention length of 4-6 weeks on HDL. Data are presented as mean difference and 95% CI using a random-effect model.
Figure 7.Forest plot showing the effects of the intervention included in the meta-analysis on LDL levels. Data are presented as mean difference and 95% CI using a random-effect model
Figure 8.Forest plot showing the effects of freeze-dried strawberry interventions on LDL levels. Data are presented as mean difference and 95% CI using a random-effect model.
Figure 9.Forest plot showing the effects of the intervention included in the meta-analysis on TC levels. Data are presented as mean difference and 95% CI using a random-effect model.
Figure 10.Forest plot showing the effects of freeze-dried strawberry interventions on TC levels. Data are presented as mean difference and 95% CI using a random-effect model.
Subgroup analysis of pooled data from the 21 studies included
| Subgroup parameter | Pooled intervention group(n) | Pooled control group(n) | Mean difference | P-value | 95% CI | Heterogeneity (I2) | p-value for heterogeneity |
|---|---|---|---|---|---|---|---|
| Fasting glucose levels | 335 | 345 | 3.29 mg/dl | 0.09 | -0.53, 7.11 | 92 | <0.00001 |
| Hb1Ac | 225 | 241 | 0.04% | 0.45 | -0.06, 0.13 | 37 | 0.12 |
| BMI change | 233 | 251 | -0.69 kg/m2 | 0.02 | -1.27, -0.12 | 0 | 0.68 |
| Insulin levels | 304 | 319 | -0.01mIU/l | 0.97 | -0.40, 0.38 | 0 | 0.47 |
| SBP | 471 | 465 | -0.30 mm Hg | 0.68 | -1.76, 1.15 | 13 | 0.3 |
| DBP | 471 | 465 | -1.05 mm Hg | 0.06 | -2.15, 0.04 | 35 | 0.08 |
| Oxidized LDL | 98 | 96 | -0.29 U/l | 0.93 | -6.99, 6.41 | 54 | 0.07 |
Legend: A negative mean difference suggests an improvement in the intervention group over the control group. Several other subgroup analyses were carried out, but on measurements other than main lipid measurements. The analysis results can be found in Appendix A4.